165 research outputs found
Tra estro e praticità, tra realismo e sogno : Bergamo Brescia Capitale Italiana della Cultura 2023 : Storia della società, della cultura, delle stituzioni
No full textNell'anno di Bergamo Brescia Capitale italiana della Cultura (2023), Archivio Bergamasco ha voluto valorizzare alcuni tesori nascosti, materiali e immateriali, delle due province. Il volume propone un percorso variegato, che dal Medioevo e i suoi conflitti giunge al Novecento, problematico secolo di cambiamenti e di orrori, passando attraverso il Rinascimento degli eruditi e delle poetesse, delle botteghe delle arti e degli artigiani; i secoli d'ancien régime e delle rappresentazioni teatrali; l'età dei Lumi e le sue riforme, per concludersi con un tesoro immateriale, il gaì, gergo ormai perduto di pastori seriani e camuni
Kinderwunsch und Krebs: Wie kann Bedürfnissen betroffener Frauen und deren Partner begegnet werden?
No full textCharacterization of ornamental Datura plants transformed by Agrobacterium rhizogenes.
No full textDatura arborea and D. sanguinea hairy roots were produced by cocultivation of leaf fragments with Agrobacteriumrhizogenes strain NCPP 1855. Adventitious buds emerged spontaneously-, without exogenous growth regulators, fiom sevenhairy root clones of D. arborea and from one hairy, root clone of D. sanguinea. Regenerated plants were successfullyacclimatized in the greenhouse. The integration of the bacterial TL-DNA into the genome of the putative transformed plantswas confirmed by Southern blot analysis. Transgenie plants displayed increased ability to root in vivo. Morphological traitswith relevant ornamental value like plant height, leaf number, size and shape, internode numbe~, and internode length werealso affected. Transformation by wild-type Ri TL-DNA provided the chance to study plant growth and differentiation andto select improved genotypes
Giovanni Battista Benevolo e i suoi incunaboli : Uso e dispersione di una raccolta libraria cinquecentesca
No full textA partire da alcune note note di possesso rinvenute in libri a stampa antichi della Biblioteca Civica A. Mai di Bergamo, il contributo indaga sul cittadino bresciano Giovanni Battista Benevolo (ca. 1468-dopo il 1524), qui identificato con il maestro Giovanni Battista Bonetti, originario della Valle Camonica, ma vissuto a Brescia sin dall'infanzia. Grazie ad alcuni documenti di prima mano se ne delineano il profilo biografico e il contesto familiare e culturale, se ne indaga l'attività editoriale al servizio dei fratelli Britannico, si descrivono dieci esemplari provenienti dalla sua biblioteca, ora conservati fra Bergamo, Genova, Lubljana e Salò. Per il lotto più rappresentativo, pervenuto alla Biblioteca A. Mai, si individua un importante canale di dispersione nella biblioteca del convento di S. Agostino di Bergam
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
No full textBackground: The International Breast Cancer Study Group Trial VIII compared long-term efficacy of endocrine therapy (goserelin), chemotherapy [cyclophosphamide, methotrexate and fluorouracil (CMF)], and chemoendocrine therapy (CMF followed by goserelin) for pre/perimenopausal women with lymph-node-negative breast cancer.
Patients and methods: From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months (n = 346), (ii) six courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or (iii) six courses of CMF plus 18 months goserelin (CMF -> goserelin; n = 357). Tumors were classified as estrogen receptor (ER) negative (19%), ER positive (80%), or ER unknown (1%); 19% of patients were younger than 40. Median follow-up was 12.1 years.
Results: For the ER-positive cohort, sequential therapy provided a statistically significant benefit in disease-free survival (DFS) (12-year DFS = 77%) compared with CMF alone (69%) and goserelin alone (68%) (P = 0.04 for each comparison), due largely to the effect in younger patients. Patients with ER-negative tumors whose treatment included CMF had similar DFS (12-year DFS CMF = 67%; 12-year DFS CMF -> goserelin = 69%) compared with goserelin alone (12-year DFS = 61%, P= NS).
Conclusions: For pre/perimenopausal women with lymph-node-negative ER-positive breast cancer, CMF followed by goserelin improved DFS in comparison with either modality alone. The improvement was the most pronounced in those aged below 40, suggesting an endocrine effect of prolonged CMF-induced amenorrhea
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
No full textBackground: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)positive lymph node-negative breast cancer is being reassessed. Patients and methods: After stratification by ER status, 1669 postmenopausal patients with operable lymph nodenegative breast cancer were randomly assigned to three 28-day courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF/tamoxifen) or to tamoxifen alone for 5 years. Results: ERs were positive in 81% of tumors. At a median follow-up of 13.1 years, patients with ER-positive breast cancers did not benefit from CMF [13-year disease-free survival (DFS) 64% CMF/tamoxifen, 66% tamoxifen; P = 0.99], whereas CMF substantially improved the prognosis of patients with ER-negative breast cancer (13-year DFS 73% versus 57%, P = 0.001). Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0.001). CMF had no influence on second nonbreast malignancies or deaths from other causes. Conclusion: CMF is not beneficial in postmenopausal patients with node-negative ER-positive breast cancer but is highly effective within the ER-negative cohort. In the future, other markers of chemotherapy response may define a subset of patients with ER-positive tumors who may benefit from adjuvant chemotherap
A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
No full textpeer reviewedBackground: The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic breast cancer (MBC), after a short induction at conventional doses. Methods: Between April 2013 and August 2015, 258 women untreated with chemotherapy for MBC were randomly assigned to receive three different maintenance chemotherapy schedules after three cycles of identical induction chemotherapy: Arm A, nab-Paclitaxel 150 mg/m2 days 1,15 Q28; Arm B, nab-Paclitaxel 100 mg/m2 days 1,8,15 Q28; Arm C, nab-Paclitaxel 75 mg/m2 days 1,8,15,22 Q28. Induction was three cycles nab-Paclitaxel 150/125 mg/m2, days 1,8,15 Q28. The primary objective was to evaluate the efficacy of each maintenance schedule, in terms of progression-free survival (PFS), as compared to the historical reference of 7-month median PFS reported by previous studies with first-line docetaxel. One-sample, one-sided log-rank tests were utilized. Quality-of-life evaluation was performed, global indicator for physical well-being was defined as the primary endpoint; completion rates of quality-of-life forms were >90%. Results: 255 patients were evaluable for the primary endpoint. After 18.2 months median follow-up, 182 PFS events were observed. Median PFS was 7.9 months (90%CI 6.8-8.4) in Arm A, 9.0 months (90%CI 8.1-10.9) in Arm B and 8.5 months (90%CI 6.7-9.5) in Arm C. PFS in Arm B was significantly longer than the historical reference of first-line docetaxel (P=0.03). Grade>/=2 sensory neuropathy was reported in 37.9%, 36.1% and 31.2% of patients in Arm A, Arm B and Arm C, respectively (Grade>/=3 in 9.1%, 5.6% and 6.6% of patients, respectively). Noteworthy, the quality-of-life scores for sensory neuropathy did not worsen with prolonged nab-Paclitaxel administration in any of the maintenance arms. Conclusion: The SNAP trial demonstrated that alternative nab-Paclitaxel maintenance schedules with reduced dosages after a short induction at conventional doses are feasible and active in the first-line treatment of MBC. Registration: ClinicalTrials.gov NCT01746225
- …
